Failure of danaparoid anticoagulation for cardiopulmonary bypass

被引：6

作者：

Ariano, RE

Bhattacharya, SK

Moon, M

Brownell, LG

机构：

[1] St Boniface Gen Hosp, Dept Pharm, Winnipeg, MB R2H 2A6, Canada

[2] St Boniface Gen Hosp, Dept Cardiac Surg, Winnipeg, MB R2H 2A6, Canada

[3] St Boniface Gen Hosp, Dept Anaesthesia, Winnipeg, MB R2H 2A6, Canada

来源：

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2000年 / 119卷 / 01期

关键词：

D O I：

10.1016/S0022-5223(00)70233-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：167 / 168

页数：2

共 5 条

[1]

HATHAWAY WE, 1991, SEMIN HEMATOL, V28, P19

[2]

Laposata M, 1998, ARCH PATHOL LAB MED, V122, P799

[3] Heparin-induced thrombocytopenia Type II: Perioperative management using danaparoid in a coronary artery bypass patient with renal failure [J].

Westphal, K ;

Martens, S ;

Strouhal, U ;

Matheis, G ;

Lindhoff-Last, E ;

Wimmer-Greinecker, G ;

Lischke, V .

THORACIC AND CARDIOVASCULAR SURGEON, 1997, 45 (06) :318-320

[4] Danaparoid - A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia [J].

Wilde, MI ;

Markham, A .

DRUGS, 1997, 54 (06) :903-924

[5] Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172 [J].

Wilhelm, MJ ;

Schmid, C ;

Kececioglu, D ;

Mollhoff, T ;

Ostermann, H ;

Scheld, HH .

ANNALS OF THORACIC SURGERY, 1996, 61 (03) :920-924

← 1 →